vTv Therapeutics Inc
NASDAQ:VTVT

Watchlist Manager
vTv Therapeutics Inc Logo
vTv Therapeutics Inc
NASDAQ:VTVT
Watchlist
Price: 15 USD -2.54% Market Closed
Market Cap: 45.2m USD
Have any thoughts about
vTv Therapeutics Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one VTVT stock under the Base Case scenario is 4.28 USD. Compared to the current market price of 15 USD, vTv Therapeutics Inc is Overvalued by 71%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VTVT Relative Value
Base Case
4.28 USD
Overvaluation 71%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

47.8
P/S
P/S
Price to Sales
47.8
vs History
80
vs Industry
22
Median 3Y
576.2
Median 5Y
981.5
Industry
7.4
Forward
46.9
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-111.5
Median 5Y
-197
Industry
21.6
Forward
-4.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-86.8
Median 5Y
-185.5
Industry
19.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-86.5
Median 5Y
-172.3
Industry
23.9
More Details
3.2
P/B
P/B
Price to Book Value
3.2
vs History
1
vs Industry
38
Median 3Y
-84.3
Median 5Y
-115.7
Industry
2.4
More Details
6.3
EV/S
EV/S
Enterprise Value to Sales
6.3
vs History
80
vs Industry
76
Median 3Y
572.7
Median 5Y
980.6
Industry
7.7
Forward
6.2
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
27
Median 3Y
-76.7
Median 5Y
-143.6
Industry
3.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
25
Median 3Y
-76.4
Median 5Y
-143.1
Industry
3.6
Forward
-0.2
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
29
Median 3Y
-86.4
Median 5Y
-184.8
Industry
4.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
25
Median 3Y
-86.4
Median 5Y
-184.8
Industry
3.2
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
67
Median 3Y
-0.4
Median 5Y
200.1
Industry
4.5
More Details

Multiples Across Competitors

VTVT Competitors Multiples
vTv Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
vTv Therapeutics Inc
NASDAQ:VTVT
47.8m USD 47.8 -2.6 -0.3 -0.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 579 455.5 -173 856.7 -211 117.5 -208 708.4
US
Abbvie Inc
NYSE:ABBV
382.5B USD 6.8 90.2 17.6 26.5
US
Amgen Inc
NASDAQ:AMGN
175.8B USD 5.3 43 17.1 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
146B USD 5.1 304.3 11.8 14.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
128.5B USD 11.7 -239.9 26.3 27.5
US
Epizyme Inc
F:EPE
94.1B EUR 1 925.9 -491.4 -535.2 -520.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.6B USD 5.7 18.5 12.7 14.2
AU
CSL Ltd
ASX:CSL
121.8B AUD 5 27.8 17.2 21.5
US
Seagen Inc
F:SGT
39.3B EUR 18.6 -56.9 -61.2 -55.2
NL
argenx SE
XBRU:ARGX
31.8B EUR 15.7 41.4 304 -2 239.9
P/S Multiple
Revenue Growth P/S to Growth
US
vTv Therapeutics Inc
NASDAQ:VTVT
Average P/S: 3 325 591.2
47.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
36 579 455.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
5.3
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
3%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.7
10%
1.2
US
E
Epizyme Inc
F:EPE
1 925.9
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
7%
0.8
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
S
Seagen Inc
F:SGT
18.6
30%
0.6
NL
argenx SE
XBRU:ARGX
15.7
37%
0.4
P/E Multiple
Earnings Growth PEG
US
vTv Therapeutics Inc
NASDAQ:VTVT
Average P/E: 87.5
Negative Multiple: -2.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -173 856.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
90.2
88%
1
US
Amgen Inc
NASDAQ:AMGN
43
44%
1
US
Gilead Sciences Inc
NASDAQ:GILD
304.3
185%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -239.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -491.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
11%
1.7
AU
CSL Ltd
ASX:CSL
27.8
16%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A N/A
NL
argenx SE
XBRU:ARGX
41.4
19%
2.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
vTv Therapeutics Inc
NASDAQ:VTVT
Average EV/EBITDA: 58.1
Negative Multiple: -0.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -211 117.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.6
13%
1.4
US
Amgen Inc
NASDAQ:AMGN
17.1
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
11.8
6%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.3
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -535.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
17%
0.7
AU
CSL Ltd
ASX:CSL
17.2
12%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.2 N/A N/A
NL
argenx SE
XBRU:ARGX
304
168%
1.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
vTv Therapeutics Inc
NASDAQ:VTVT
Average EV/EBIT: 22.5
Negative Multiple: -0.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 708.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
26.5
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
30.4
31%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.9
10%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.5
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -520.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.2
17%
0.8
AU
CSL Ltd
ASX:CSL
21.5
14%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.2 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 239.9 N/A N/A

See Also

Summary
VTVT intrinsic value, competitors valuation, and company profile.
DCF Valuation
VTVT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VTVT stock valuation using valuation multiples.
Wall Street Estimates
VTVT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VTVT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 237,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.